Hexarelin vs Ipamorelin

Hexarelin is a synthetic hexapeptide that acts as a potent growth hormone secretagogue through ghrelin receptor (GHS-R1a) agonism. In addition to stimulating GH release, hexarelin has been shown to affect cortisol and prolactin levels in preclinical models, and has documented cardioprotective properties through CD36 receptor binding independent of its GH-releasing activity. Ipamorelin is a synthetic pentapeptide and selective ghrelin receptor agonist that stimulates pulsatile growth hormone release. Its defining characteristic is selectivity — unlike hexarelin and other GHRPs, ipamorelin does not significantly affect cortisol, prolactin, or aldosterone in preclinical models. This makes it one of the cleanest GH secretagogues available for isolated GH axis research.

Hexarelin

Class Ghrelin mimetic (GHS)
Potency Highly potent
Cortisol Effect Yes (significant in study models)
Prolactin Effect Yes
Additional Mechanisms CD36 binding (cardioprotective research)
Research Focus GH axis, cardiac, multi-pathway

Ipamorelin

Class Selective ghrelin mimetic
Potency Moderate potency
Cortisol Effect Minimal to none
Prolactin Effect Minimal
Additional Mechanisms GHS-R1a only
Research Focus Isolated GH research, secretagogue selectivity

The Verdict

Hexarelin and ipamorelin both stimulate GH release through ghrelin receptor activation, but their specificity profiles differ dramatically. Hexarelin is more potent and produces broader effects across multiple pathways including cortisol, prolactin, and CD36-mediated cardiac signaling. Ipamorelin is the cleaner research tool when isolated GH axis effects are needed without confounding hormonal changes. Researchers focused specifically on growth hormone biology typically prefer ipamorelin, while those investigating multi-pathway effects or cardiac mechanisms may select hexarelin.

Explore These Products

Hexarelin

A synthetic hexapeptide and one of the most potent growth hormone-releasing peptides studied, with additional cardioprotective properties via CD36 receptor binding.

View Details →

Ipamorelin

A selective growth hormone secretagogue that mimics ghrelin, studied for its ability to release GH without affecting cortisol or prolactin levels.

View Details →

Hexarelin vs Ipamorelin — FAQ

Why is ipamorelin considered "selective"?
Ipamorelin selectively activates the GHS-R1a receptor without significantly affecting cortisol, prolactin, or aldosterone secretion in preclinical models. Most other GHRPs cause measurable changes in these hormones.
What is the cardiac connection with hexarelin?
Hexarelin binds to the CD36 receptor in addition to the ghrelin receptor. CD36 is expressed in cardiac tissue and has been studied for cardioprotective signaling independent of GH release.
Can they be compared in the same study?
Yes. Comparative studies are common to isolate which effects are receptor-specific (GH only) versus broader (cortisol, prolactin, cardiac).
What is the regulatory status?
Both are sold as research-use-only compounds for in-vitro and preclinical study models.

References

Primary sources for key clinical and regulatory claims on this page.

  1. Hexarelin: a synthetic GH-releasing peptide with multiple actions — PubMed / J Endocrinol Invest . Primary reference for hexarelin GH-releasing potency and broader hormonal effects.
  2. Ipamorelin, the first selective growth hormone secretagogue — PubMed / Eur J Endocrinol . Foundational source establishing ipamorelin selectivity profile in preclinical models.

Keep Researching

Use the surrounding category and guide pages to move from a side-by-side comparison into the broader decision path.

Research Peptides CategoryGrowth-Hormone Hub
Updated March 2026. This comparison is reviewed for catalog accuracy, sourcing language, and consistency with our public quality standards. It is an educational summary for research reference only. Read our Editorial Standards.

Ready to order?

Pick your product and check out in under 3 minutes.

Shop Now